RxDoctor Payments DataLook up a doctor →

Jesse Jorgensen, MD

Interventional Cardiology · Greenville, SCNPI 1154401206

Payments from drug & device makers

$196,928in general payments, 2019–2025

Across 707 payments — averaging $278.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$84K
  • Johnson & Johnson$70K
  • Abbott$21K
  • AstraZeneca$6K
  • Biotronik Inc.$3K
  • Edwards Lifesciences$3K
  • plus $9K from 42 others

What the payments were for

  • Consulting fees$2,4252%
  • Speaking & faculty fees$72,32071%
  • Grants$540%
  • Travel & lodging$6,9857%
  • Food & beverage$19,74319%
  • Education$2480%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$196,928 in reported general payments places this provider in the 90th percentile of 117 interventional cardiology providers in South Carolina.

See all interventional cardiology providers in South Carolina

Medicare billing

Part B allowed, 2024
$246,241
Medicare patients
1,050
Services billed
2,212

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban155$162,720
Repatha SureclickEvolocumab127$116,556
XareltoRivaroxaban119$103,588
BrilintaTicagrelor16$8,818
Praluent PenAlirocumab13$8,313
Ranolazine ErRanolazine53$6,468
Atorvastatin Calcium250$2,520
Rosuvastatin Calcium173$2,182
ClopidogrelClopidogrel Bisulfate153$1,444
Isosorbide Mononitrate ErIsosorbide Mononitrate76$1,397
Losartan Potassium137$1,391
Metoprolol Succinate122$1,367
Carvedilol120$878
Furosemide154$785
Lisinopril119$657

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$40$162,720155 claims
Johnson & JohnsonXarelto$69,998$103,588119 claims
AstraZenecaBrilinta$6,343$8,81816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 117 interventional cardiology providers in South Carolina.

Other interventional cardiology in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →